Simon Read

CIK: 0001688199

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)7 (63.6%)

Position reduction

Option Exercises (M)2 (18.2%)

Derivative conversions

Awards (A)2 (18.2%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

DNTH

Dianthus Therapeutics, Inc. /DE/

Director

Discretionary Trading P&L

Holdings

Transaction History (11 total)

DNTH
Dianthus Therapeutics, Inc. /DE/
Aug 19, 2026
Exercise(M)
Direct
2.8K shares at avg. $18.36$51K
DNTH
Dianthus Therapeutics, Inc. /DE/
Aug 19, 2026
Sale(S)
Direct
2.8K shares at avg. $117.55$327K
DNTH
Dianthus Therapeutics, Inc. /DE/
Aug 10, 2026
Sale(S)
Direct
737 shares at avg. $108.17$80K
DNTH
Dianthus Therapeutics, Inc. /DE/
Aug 10, 2026
Sale(S)
Direct
831 shares at avg. $108.95$91K
DNTH
Dianthus Therapeutics, Inc. /DE/
Aug 10, 2026
Sale(S)
Direct
272 shares at avg. $109.96$30K
DNTH
Dianthus Therapeutics, Inc. /DE/
Aug 10, 2026
Sale(S)
Direct
470 shares at avg. $111.05$52K
DNTH
Dianthus Therapeutics, Inc. /DE/
Aug 10, 2026
Sale(S)
Direct
397 shares at avg. $111.77$44K
DNTH
Dianthus Therapeutics, Inc. /DE/
Aug 10, 2026
Exercise(M)
Direct
2.8K shares at avg. $18.36$51K
DNTH
Dianthus Therapeutics, Inc. /DE/
Aug 10, 2026
Sale(S)
Direct
70 shares at avg. $107.11$7K
DNTH
Dianthus Therapeutics, Inc. /DE/
May 21, 2026
Award(A)
Stock Option (Right to Buy)
Direct
6.1K shares-
DNTH
Dianthus Therapeutics, Inc. /DE/
May 22, 2025
Award(A)
Stock Option (Right to Buy)
Direct
25K shares-

		Type	Shares	Price		Ownership
Aug 19, 2026	DNTH Dianthus Therapeutics, Inc. /DE/	Exercise(M)	2,778	$18.36	$51,004	Direct
Aug 19, 2026	DNTH Dianthus Therapeutics, Inc. /DE/	Sale(S)	2,778	$117.55	$326,554	Direct
Aug 10, 2026	DNTH Dianthus Therapeutics, Inc. /DE/	Sale(S)	737	$108.17	$79,721	Direct
Aug 10, 2026	DNTH Dianthus Therapeutics, Inc. /DE/	Sale(S)	831	$108.95	$90,537	Direct
Aug 10, 2026	DNTH Dianthus Therapeutics, Inc. /DE/	Sale(S)	272	$109.96	$29,909	Direct
Aug 10, 2026	DNTH Dianthus Therapeutics, Inc. /DE/	Sale(S)	470	$111.05	$52,194	Direct
Aug 10, 2026	DNTH Dianthus Therapeutics, Inc. /DE/	Sale(S)	397	$111.77	$44,373	Direct
Aug 10, 2026	DNTH Dianthus Therapeutics, Inc. /DE/	Exercise(M)	2,777	$18.36	$50,986	Direct
Aug 10, 2026	DNTH Dianthus Therapeutics, Inc. /DE/	Sale(S)	70	$107.11	$7,498	Direct
May 21, 2026	DNTH Dianthus Therapeutics, Inc. /DE/	Award(A) Stock Option (Right to Buy)	6,090	-	-	Direct
May 22, 2025	DNTH Dianthus Therapeutics, Inc. /DE/	Award(A) Stock Option (Right to Buy)	25,000	-	-	Direct

1-11 of 11 transactions

About Read Simon

Read Simon (SEC CIK 0001688199) files insider reports with the SEC as Director of Dianthus Therapeutics, Inc. /DE/ (DNTH).

Signal8 holds 5 ownership filings by Read Simon (1 Form 3, 4 Form 4), filed between May 22, 2025 and Aug 19, 2026. Those filings report 11 transactions, from May 22, 2025 to Aug 19, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Read Simon's filings is in NEW YORK, NY.

Recent filings by Read Simon

Aug 19, 2026: Option exercise of DNTH shares (Form 4, code M).
Aug 19, 2026: Open-market sale of DNTH shares (Form 4, code S).
Aug 10, 2026: Open-market sales of DNTH shares (5 lines, Form 4, code S).
Aug 10, 2026: Option exercise of DNTH shares (Form 4, code M).
Aug 10, 2026: Open-market sale of DNTH shares (Form 4, code S).

Other insiders filing for Dianthus Therapeutics, Inc. /DE/ (DNTH)

CARR EDWARD, CHIEF ACCOUNTING OFFICER
Randhawa Simrat, EVP, Head of R&D
Veness Adam M, SVP, General Counsel and Sec.
McGeorge Anne, Director
Garcia Marino, CEO AND PRESIDENT
Savitz Ryan, EVP, CFO & CBO

How to read Form 4 transaction codes